Dr Pratz speaks with ecancer at the 2017 ASH annual meeting about data from a phase I study of gilteritinib in newly diagnosed FLT3mut AML patients.
Gilteritinib is already in phase III studies for relapsed/refractory AML patients.
For more on gilteritinib, watch our interview with Dr Jessica Altman at EHA 2017
ecancer’s filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.